EichorEICHOR
Study identifier: NCT07429071 Synced from ClinicalTrials.gov · August 10, 2026
● Study status: Recruiting

Effectiveness of a Vaginal Gel on CIN1/2 Regression and HPV Clearance.

Condition: Womens Health · Cervical Dysplasia · Cervical Intraepithelial Neoplasia (CIN)  ·  Sponsor: University of Aarhus

PhaseNA
Planned participants70
Who can joinFemale, 30 Years to 50 Years
Healthy volunteersNoCheck eligibility criteria ↓
Where2 locations

Interested? Contact the study team ↓

For sponsors, CROs & site teams
Professional view of this study — listed sites, countries and recruiting context from the public registry. Everything below is written for patients and caregivers.See where this study is running →

About this study

The goal of this clinical trial is to evaluate whether a Coriolus versicolor-based vaginal gel facilitates HPV clearance in women aged 30-50 years diagnosed with HPV and CIN1 or CIN2. In addition, the study will investigate whether the gel promotes regression of CIN1/CIN2, assessment of patient satisfaction, treatment compliance and characterize the vaginal microbiome. The primary outcomes therefore is: • hrHPV clearance from baseline to follow-up (6 months) In this randomized controlled study, eligible participants will be randomized 1:1 into two groups: 1. Intervention group: Women (n=35) will apply a CV-based vaginal gel (Papilocare®) daily for 21 days for 3 months. Afterward, the gel should be used every other day for an additional 3 months. Every month includes a 7-day break due to menstruation (28 days cycle). 2. Control group; Women (n=35) will follow the conventional "wait and see" approach.

This description comes directly from the study's public registry record.

Talk to the study team

Pinar Bor, Professor, MD, Ph.D.  ·  22504767  ·  isipinbo@rm.dk

Vibe M Bertelsen, Post.Doc, MD, Ph.D.  ·  vibebert@rm.dk

There is no obligation to join — the study team can answer your questions about taking part.

Always discuss trial participation with your own doctor first.

Full eligibility criteria (exactly as the study team wrote them)

Inclusion criteria: * Aged 30-50 years * A positive hrHPV test with histopathological confirmed CIN1 or CIN2 * Managed under a 'watchful waiting' strategy as part of standard management * Understand Danish, both written and orally Exclusion criteria: * Pregnancy or breastfeeding * Unexplained vaginal bleeding * Immunosuppressive or immunomodulatory conditions or treatment * Diabetes mellitus * Prior hysterectomy * Any ongoing cancer diagnosis, prior CIN3 or a history of malignancy in the genital/anal region within 5 years (excl. non-melanoma skin cancer)

Reproduced word-for-word from the public registry record — the study team can answer questions about it.

Locations (2)

Department of Gynaecology and ObstetricsHorsens, DenmarkRecruiting
Department of Gynaecology and ObstetricsRanders, DenmarkRecruiting

More studies in these areas

This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.

HorsensRanders

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →